why choose us

First received: April 10, 2023

Clinical Trial: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Pati

Brief Summary: Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death.The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab.Livmoniplimab is an investigational drug being developed for the treatment of HCC.There are 3 treatment arms in this study and participants will be randomized in a 1:1:1…

Read more